Sicca symptoms | Secondary Sjögren's syndrome | ||||||
---|---|---|---|---|---|---|---|
Present (n=49) | Absent (n=32) | Present (n=9) | Absent (n=72) | ||||
Demographics | |||||||
Female sex | 44 (90) | 28 (88) | 9 (100) | 63 (88) | |||
Age | 44.8 (12.7) | 44.1 (12.4) | 48.6 (11.1) | 44.0 (12.6) | |||
Smokers (current) | 17 (35) | 9 (29) | 4 (44) | 22 (31) | |||
Xerogenic drugs | 14 (29)5-150 | 3 (9) | 3 (33) | 14 (19) | |||
Disease variables | |||||||
Age at disease onset | 34.6 (13.4) | 36.8 (12.7) | 37.5 (11.8) | 35.2 (13.3) | |||
Disease duration | 8.3 (5.5) | 7.0 (4.7) | 8.0 (5.1) | 7.2 (5.3) | |||
Disease activity (SLEDAI) | 6.67 (5.5) | 6.68 (5.9) | 6.67 (6.0) | 6.68 (5.6) | |||
Organ damage (SLICC/ACR-DI) | 2.42 (2.4)5-150 | 1.13 (1.5) | 1.89 (3.8) | 1.91 (1.9) | |||
Number of ARA/ACR criteria | 5.49 (1.4) | 5.53 (1.2) | 5.4 (0.9) | 5.5 (1.4) | |||
ESR (mm/1st h) | 26.5 (20.3) | 22.1 (20.9) | 26.1 (11.2) | 24.6 (20.4) | |||
Anti-dsDNA antibody | 29 (59) | 18 (56) | 4 (44) | 43 (60) | |||
Anti-SSA antibody | 16 (33) | 16 (50) | 8 (89)5-150 | 26 (36) | |||
Anti-SSB antibody | 8 (16) | 5 (16) | 5 (56)5-150 | 8 (11) | |||
C3 decreased (<0.67 g/l) | 4 (8) | 4 (13) | 1 (11) | 7 (10) | |||
C4 decreased(<0.13 g/l) | 18 (37) | 11 (34) | 5 (56) | 24 (33) | |||
Renal disorder | 8 (16) | 6 (19) | 05-150 | 14 (19) | |||
Health status measures | |||||||
SF-36 physical | 61.6 (27.1)5-150 | 75.8 (21.9) | 58.9 (33.7) | 68.2 (24.9) | |||
SF-36 bodily pain | 47.1 (23.8)5-150 | 58.9 (27.6) | 51.3 (31.7) | 51.8 (25.3) | |||
SF-36 vitality | 33.2 (22.2)5-150 | 46.5 (21.0) | 25.6 (18.8)5-150 | 40.1 (22.5) | |||
SF-36 general health | 40.3 (25.5)5-150 | 53.5 (27.8) | 39.9 (25.3) | 46.2 (27.3) | |||
SF-36 mental | 69.8 (17.9) | 73.0 (16.0) | 76.0 (12.9) | 70.5 (17.6) | |||
SF-36 social | 64.5 (23.4)5-150 | 75.4 (24.1) | 61.1 (20.2) | 69.8 (24.5) | |||
MHAQ | 1.44 (0.49)5-150 | 1.12 (0.24) | 1.44 (0.53) | 1.30 (0.43) | |||
VAS pain | 37.7 (21.3)5-150 | 26.3 (23.9) | 31.9 (25.6) | 33.4 (22.8) | |||
VAS fatigue | 60.6 (26.3)5-150 | 38.9 (30.3) | 68.7 (23.1)5-150 | 48.6 (29.9) | |||
Patient global assessment | 2.73 (0.91) | 2.44 (1.01) | 2.78 (0.83) | 2.60 (0.97) |
Two sample t test for continuous and χ2 for categorical variables.
↵5-150 p<0.05.